Summer is upon us and it’s time for a news update from biotech company Aqilion. CEO Sarah Fredriksson came to BioStock’s studio to provide an insight into the company’s progress during the year. She talks about the FDA approval of AQ280, the timeline for the ARIA-2 study and the resumption of the TAK1 program. She also provides an update on Aqilion’s financial situation and shares the goals for the rest of the year.
Watch the interview with the CEO Sarah Fredriksson, in English, below.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.